Oruka Therapeutics Files 8-K with Key Agreements and Filings
Ticker: ORKA · Form: 8-K · Filed: Sep 13, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Oruka Therapeutics, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $23, $23,000, $22.999, $200.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-filing
TL;DR
Oruka Therapeutics dropped an 8-K detailing material agreements, equity sales, and corporate changes. Check it out.
AI Summary
Oruka Therapeutics, Inc. entered into a Material Definitive Agreement on September 11, 2024. The company also reported on unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. Additionally, a Regulation FD Disclosure and financial statements/exhibits were filed.
Why It Matters
This 8-K filing indicates significant corporate actions and potential strategic shifts for Oruka Therapeutics, impacting investors and stakeholders.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can carry inherent risks and require further investigation.
Key Players & Entities
- Oruka Therapeutics, Inc. (company) — Registrant
- September 11, 2024 (date) — Date of earliest event reported
- ARCA biopharma, Inc. (company) — Former company name
- NUVELO INC (company) — Former company name
- HYSEQ INC (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement entered into by Oruka Therapeutics?
The filing indicates the entry into a Material Definitive Agreement on September 11, 2024, but the specific details of the agreement are not provided in this summary.
What type of equity securities were sold under the unregistered sales of equity securities item?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in this summary.
Were there any changes to Oruka Therapeutics' fiscal year?
The filing lists 'Change in Fiscal Year' as an item information, suggesting a potential change, but the specifics are not detailed here.
What is the purpose of the Regulation FD Disclosure filed by Oruka Therapeutics?
The filing includes a Regulation FD Disclosure, which is typically made to ensure broad public dissemination of material non-public information, but the content is not specified.
What financial statements and exhibits are included with this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific contents are not detailed in this summary.
Filing Stats: 2,118 words · 8 min read · ~7 pages · Grade level 12.3 · Accepted 2024-09-13 16:02:39
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ORKA The Nasdaq Global Ma
- $23 — Common Stock"), at a price per share of $23.00, (ii) an aggregate of 2,439 shares (
- $23,000 — ferred Stock"), at a price per share of $23,000.00, and (iii) pre-funded warrants (the
- $22.999 — Warrant Shares") at a purchase price of $22.999 per Pre-Funded Warrant, which represent
- $200.5 million — gregate purchase price of approximately $200.5 million. Each Preferred Share is convertible
Filing Documents
- ea0214439-8k_oruka.htm (8-K) — 64KB
- ea021443901ex3-1_oruka.htm (EX-3.1) — 97KB
- ea021443901ex4-1_oruka.htm (EX-4.1) — 75KB
- ea021443901ex10-1_oruka.htm (EX-10.1) — 400KB
- ea021443901ex10-2_oruka.htm (EX-10.2) — 107KB
- ea021443901ex99-1_oruka.htm (EX-99.1) — 15KB
- ea021443901ex99-2_oruka.htm (EX-99.2) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-24-078549.txt ( ) — 1106KB
- orka-20240911.xsd (EX-101.SCH) — 3KB
- orka-20240911_lab.xml (EX-101.LAB) — 33KB
- orka-20240911_pre.xml (EX-101.PRE) — 22KB
- ea0214439-8k_oruka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oruka Therapeutics, Inc. (Registrant) Date: September 13, 2024 By: /s/ Lawrence Klein Name: Lawrence Klein Title: President and Chief Executive Officer 4